——A First-in-Class Hydrolysis-Activated Liver-Targeted THR-β Prodrug Demonstrating A Dual Advantage of Fat Reduction and Muscle Preservation SHANGHAI, May 16, 2025 /PRNewswire/ -- At the European Association for the Study of the Liver (EASL) Annual Congress, CureGene Pharmaceuticals...
Read More Details
Finally We wish PressBee provided you with enough information of ( 2025 EASL Congress Spotlight: CG-0416 Preclinical Data Unveils A Groundbreaking Dual-Action Therapy Targeting Obesity and MASH )
Also on site :
- Oscar Winner Stuns On The Red Carpet As The Cannes ‘Godmother’ — What The Prestigious Title Means
- Is Apple Pay Down? What We Know About the Widespread Outages
- Negotiation paths between Syria and Israel: Normalization postponed